View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 10, 2022

Bharat Biotech reports positive data from Covid-19 booster dose trial

Antibody titers at day 28 following the booster vaccine were greater than those reported after the primary series.

Biotechnology company and Ocugen partner Bharat Biotech has reported positive data from a Phase II analysis of booster shot of the investigational vaccine candidate for Covid-19, Covaxin (BBV152), in subjects aged 12 to 64 years. 

Administered six months after the second dose, the booster offered a substantial rise in neutralising titers in subjects, the findings showed.

Neutralising titers serve as key vaccine efficacy predictors. 

A highly purified and inactivated vaccine, Covaxin is produced by leveraging a vero cell manufacturing platform.

Bharat Biotech developed the vaccine in partnership with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). 

Additional analysis data showed that over 75% of all subjects had an identifiable neutralising antibody response six months after receiving the second vaccine dose. 

On administering the booster shot, trial subjects demonstrated a rise in antibody titers at day 28, which were found to be greater than those observed after the initial two-dose vaccine regimen. 

Furthermore, wild-type neutralising antibodies (PRNT₅₀) GMTs against Alpha, Beta, Delta and Delta plus SARS-CoV-2 variants at one month following booster rose 10·9, 161·0, 264·7, and 174·2 fold from baseline at six months following the second vaccine, respectively.

No serious adverse events, including hospital admission or mortality, were observed in the booster dose assessment.

Ocugen Clinical Development associate vice-president Huma Qamar said: “Although protection against severe disease remains high six months following the second dose, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected and consistent with what we are seeing with other vaccines. 

“Based on emerging data, a third dose may be beneficial to maintain the highest levels of protection.”

In December last year, Covaxin obtained Emergency Use Authorization (EUA) from the Drug Controller General of India for usage in children aged 12 to 18 years.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy